- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GSK
Recent news which mentions GSK
Earnings Scheduled For October 27, 2021
October 27, 2021
From Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
October 26, 2021
From Benzinga
Investing $100,000 in These 3 Dividend Stocks Could Give You Annual Income of $7,700
October 24, 2021
From Motley Fool
From Motley Fool
Why 23andMe Stock Has Jumped 16% So Far This Week
October 21, 2021
From Motley Fool
From Motley Fool
Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?
October 17, 2021
From Motley Fool
23andMe Stock Could Be a Big Winner If This 1 Thing Happens
October 17, 2021
From Motley Fool
3 Top Stocks You Can Still Buy for Under $20 a Share
October 15, 2021
From Motley Fool
Got $5,000? 3 Top Dividend Stocks to Buy Right Now
October 13, 2021
From Motley Fool
Why CureVac Stock Is Tumbling Today
October 12, 2021
From Motley Fool
From MarketWatch
Winners and Losers of Rising Energy Prices
October 12, 2021
From Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
From Benzinga
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
October 12, 2021
From Motley Fool
Why Did Ocugen Stock Skyrocket On Monday?
October 12, 2021
From Benzinga
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
October 11, 2021
From Benzinga
Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline
October 11, 2021
From Motley Fool
Moderna Stock Looks Fully Valued Here, But It Has a Great Future
October 08, 2021
Tags
NASDAQ:MRNA,NYSE:MRK,NYSE:AZN,NASDAQ:BNTX,NYSE:PFE,NASDAQ:GILD,NYSE:GSK,NYSE:SNE
Market News
GILD
From InvestorPlace
Is Xenon Pharmaceuticals a Good Stock to Buy Now?
October 05, 2021
From Motley Fool
Tesla and Merck Give Investors Some Hope
October 04, 2021
From Benzinga
Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months
October 04, 2021
From Motley Fool
From MarketWatch
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Why Alexandria Real Estate May Be a Dividend Investor's Dream
September 29, 2021
From Motley Fool
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
September 29, 2021
From Benzinga
ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi
September 28, 2021
From Benzinga
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
September 28, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.